Literature DB >> 19040291

Correlation between polymorphisms at interleukin-6 but not at interleukin-10 promoter and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Brazilian individuals.

Sandra Rocha Gadelha1, Luiz Carlos Junior Alcântara, Gisele Calazans Costa, Angelina Xavier Acosta, Domingos Rios, Simone Kashima, Dimas Tadeu Covas, Bernardo Galvão-Castro.   

Abstract

HTLV-1 is the etiologic agent of ATL and HAM/TSP. The majority of HTLV-1-infected individuals remain asymptomatic, indicating that the infection alone is not sufficient to cause the diseases. It has been reported that cytokine gene polymorphisms, including polymorphisms at IL-6 and IL-10 gene, might be important. We analyzed SNP in the promoter region of the IL-6: -174, -572, -597, and -634 positions, and IL-10: -592 position to evaluate the role of these polymorphisms in the HAM/TSP pathogenesis in 133 HTLV-1 infected individuals and in 100 healthy individuals from Salvador, Bahia, Brazil. The -634C allele frequencies were higher among HAM/TSP patients (21.2%) than among oligosymptomatic (6.5%; P = 0.038) and asymptomatic (9.5%; P = 0.025) subjects. Similarly, the -174G allele frequencies were higher in HAM/TSP patients than in oligosymptomatic patients (P = 0.02). Moreover, the -634GC/-174GG genotype combination was identified at a higher frequency (38.5%) in the HAM/TSP patients than in subjects with other clinical status (8.7%; P = 0.016 for oligosymptomatic and 15.5%, P = 0.012 for asymptomatic patients). However, the multivariate logistic regression including the genotypes of the three studied loci showed that only -634 C IL-6 carriers remain as significant and independent TSP/HAM predictor (odds ratio [OR] = 5.31; 95% [CI] = 1.60-17.56; P = 0.006). We suggest that -634 G C in IL-6 could contribute to HAM/TSP development and that identification of the collective influence of several cytokine polymorphisms, their prevalence, and their interaction could help to better understand this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19040291     DOI: 10.1002/jmv.21341

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.

Authors:  Leila Sawada; Yoshiko Nagano; Atsuhiko Hasegawa; Hikari Kanai; Kai Nogami; Sayaka Ito; Tomoo Sato; Yoshihisa Yamano; Yuetsu Tanaka; Takao Masuda; Mari Kannagi
Journal:  PLoS Pathog       Date:  2017-09-14       Impact factor: 6.823

2.  Lack of association between single-nucleotide polymorphisms of pro- and anti-inflammatory cytokines and HTLV-1-associated myelopathy / tropical spastic paraparesis development in patients from Rio de Janeiro, Brazil.

Authors:  Doris Schor; Luís Cristóvão Porto; Eric Henrique Roma; Marcel de Souza Borges Quintana; Gustavo Milson Fabricio-Silva; Maria Gloria Bonecini-Almeida; Abelardo Queiroz-Campos Araújo; Maria Jose Andrada-Serpa
Journal:  BMC Infect Dis       Date:  2018-11-22       Impact factor: 3.090

Review 3.  Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL.

Authors:  Mari Kannagi; Atsuhiko Hasegawa; Yoshiko Nagano; Shuichi Kimpara; Youko Suehiro
Journal:  Retrovirology       Date:  2019-08-22       Impact factor: 4.602

4.  Optimized PCR with sequence specific primers (PCR-SSP) for fast and efficient determination of Interleukin-6 Promoter -597/-572/-174Haplotypes.

Authors:  Michael Müller-Steinhardt; Friederike Schulte; Harald Klüter; Peter Bugert
Journal:  BMC Res Notes       Date:  2009-12-10

5.  Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load.

Authors:  Sabri Saeed Sanabani; Youko Nukui; Juliana Pereira; Antonio Charlys da Costa; Ana Carolina Soares de Oliveira; Rodrigo Pessôa; Fabio Eudes Leal; Aluisio C Segurado; Esper Georges Kallas; Ester Cerdeira Sabino
Journal:  BMC Infect Dis       Date:  2012-12-23       Impact factor: 3.090

Review 6.  Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons.

Authors:  Antonio Carlos Rosário Vallinoto; Izaura Cayres-Vallinoto; Maria Alice Freitas Queiroz; Marluísa de Oliveira Guimarães Ishak; Ricardo Ishak
Journal:  Viruses       Date:  2019-10-23       Impact factor: 5.048

Review 7.  Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Retrovirology       Date:  2019-11-29       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.